Our meta-analysis of the clinical data showed that Sec61α high expression was negatively correlated with the survival rates of the TNBC patients, while there was no significant correlation between Sec61α level and the survival rates for other types of breast cancer, such as HR-positive and HER2-positive breast cancer. The gene discussed is SEC61A1; the disease is breast cancer.